Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects, greater than 17 years of age~* Written informed consent has been obtained~* Ability to follow study instructions and likely to complete all required visits~* Written authorization for Use and Release of Health and Research Study Information has been obtained~* Subject meets the following criteria: clinical diagnosis of urinary urge incontinence with resistance to or intolerance of anticholinergic medication~* Anticholinergic medications allowed~* Willingness and ability to use self-catheterization if necessary~Exclusion Criteria:~* Uncontrolled clinically significant medical condition other than the condition under evaluation~* Known allergy or sensitivity to any of the components in the study medication~* Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study~* Concurrent participation in another investigational drug or device study~* Treatment with botulinum toxin of any serotype for urological condition prior to enrolment in study (if applicable)~* Any medical condition that may put the subject at increased risk with exposure to botulinum toxin A including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function~* Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study~* Symptomatic urinary retention or post-void residual of \>200ml~* Anticoagulation therapy within 3 days of injection procedure~* Familial bleeding disorder~* UUI secondary to neurologic disease~* Myasthenia gravis~* Previous bladder pathology (e.g. transitional cell carcinoma)

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebos (Type: PLACEBO_COMPARATOR): Placebo injected into the detrusor at Day 1,
- Botulinum Toxins, Type A (Type: EXPERIMENTAL): Botulinum Toxins, Type A 100U injected into the detrusor at Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).